Latest News

Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.

In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.

The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.

Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.

Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early-career physicians building new programs.

Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.

Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.

Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer.

Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.

Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.

Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.

Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.

Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.

Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.

In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.

Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.

Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.

Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.

Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.

Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.

Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.

Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.

Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.

Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.

A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.

The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.

Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.

In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.

Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.